IRIS
CASSANITI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 733
EU - Europa 504
AS - Asia 123
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 729
IE - Irlanda 212
IT - Italia 164
CN - Cina 101
FI - Finlandia 60
DE - Germania 39
JP - Giappone 10
SE - Svezia 10
BE - Belgio 7
IN - India 7
AU - Australia 3
CA - Canada 3
IR - Iran 3
NL - Olanda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
RO - Romania 2
UA - Ucraina 2
BR - Brasile 1
CH - Svizzera 1
FR - Francia 1
GB - Regno Unito 1
IL - Israele 1
MX - Messico 1
RU - Federazione Russa 1
SG - Singapore 1
SI - Slovenia 1
Totale 1.366
Salva come PNG Salva come JPEG
Città #
Dublin 194
Chandler 175
Ashburn 87
New York 80
Helsinki 60
Shanghai 50
Seattle 33
Princeton 31
Beijing 30
Milan 30
Lawrence 26
Medford 21
Pavia 18
Wilmington 16
Rome 11
Washington 11
Los Angeles 10
Lecce 8
Brussels 5
Nanjing 5
Pune 5
Ann Arbor 4
Corsico 4
Fairfield 4
Menlo Park 4
Norwalk 4
Woodbridge 4
Boves 3
Bovisio Masciago 3
Cascina 3
Hangzhou 3
Lodi 3
Marcignago 3
Shenyang 3
Toronto 3
Alghero 2
Amsterdam 2
Bereguardo 2
Bergamo 2
Brescia 2
Domodossola 2
Hebei 2
Jette 2
Muggiò 2
San Francisco 2
Serrone 2
Taranto 2
Turin 2
Berlin 1
Borca 1
Bromma 1
Changsha 1
Chiasso 1
Como 1
Falkenstein 1
Ferrara di Monte Baldo 1
Frankfurt am Main 1
Gallarate 1
Gunzenhausen 1
Gurgaon 1
Gustavo Adolfo Madero 1
Haifa 1
Hanover 1
Huddinge 1
Jacksonville 1
Kemerovo 1
Leawood 1
Ljubljana 1
London 1
Melbourne 1
Minoh 1
Mogliano Veneto 1
Motta Visconti 1
Munich 1
Nanchang 1
Nandyal 1
Naples 1
Paris 1
Rovello Porro 1
San Diego 1
Serramanna 1
Singapore 1
Tianjin 1
Zanjan 1
Totale 1.016
Salva come PNG Salva come JPEG
Nome #
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers 50
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 50
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 49
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 47
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 47
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 46
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study 46
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 41
Human Cytomegalovirus-Specific Memory CD4+T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection 39
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020 37
Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017 35
Characterization of varicella-zoster (Vzv) specific t cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (elispot) assays 35
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission 34
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay 33
Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas 33
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors 33
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 32
Zika virus infection in pregnancy: Advanced diagnostic approaches in dengue-naive and dengue-experienced pregnant women and possible implication for cross-reactivity and cross-protection 31
Sars-cov-2 virologic and immunologic correlates in patients with olfactory and taste disorders 31
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 31
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department 30
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 30
Authors' response: COVID-19: how accurate are seroprevalence studies? 28
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 28
19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of Concern 26
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients 26
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 24
CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection 24
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection 22
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 20
Deep learning and machine learning-based voice analysis for the detection of COVID-19: A proposal and comparison of architectures 19
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "I Am like a Box of Complexity, You Never Know What You Are Gonna Get" 19
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis 17
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 16
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 16
Photopheresis abates the anti-hla antibody titer and renal failure progression in chronic antibody-mediated rejection 16
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 15
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 15
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 14
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects 14
Immune response to bnt162b2 in solid organ transplant recipients: Negative impact of mycophenolate and high responsiveness of sars-cov-2 recovered subjects against delta variant 14
Immunity to SARS-CoV-2 up to 15 months after infection 13
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 13
West nile or usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors 13
SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment 12
The 'hit-and-run' strategy and viral carcinogenesis 12
Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study 11
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment 11
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice 11
Macrophages and monocytes: “trojan horses” in covid-19 10
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 10
Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital 10
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 10
Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19 9
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice 9
Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? 9
Infectious complications and immunotherapy: old pitfalls and new horizons 9
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19 9
Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children 9
Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study 8
Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein 8
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) 7
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get” 7
ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients 5
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients 5
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 3
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant 3
Corrigendum to "Seroprevalence of SARS-CoV-2 in 1922 blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area" [Clin Microbiol Infect 27 (6) (2021 Jun) 914.e1-914.e4] 2
Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients 2
Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers 1
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology 1
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 1
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant 1
Preliminary results on an autochthonous dengue outbreak in Lombardy Region, Italy, August 2023 1
Asymptomatic infection with clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) in carnivore pets, Italy, April 2023 1
Totale 1.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.616
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.616
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202042 8 10 0 0 0 0 0 2 0 6 16 0
2020/202139 0 0 17 0 4 1 2 8 4 0 3 0
2021/2022181 2 1 5 26 12 3 4 12 4 17 16 79
2022/2023610 40 51 6 48 31 38 4 16 271 12 81 12
2023/2024583 59 111 41 29 54 157 59 44 6 22 1 0
Totale 1.459